Cytori Therapeutics (NASDAQ: CYTX) has completed its acquisition of Azaya Therapeutics, which will provide Cytori with a proprietary liposomal nanoparticle technology platform and two nanoparticle oncology drugs. The pickup comes with the relatively modest price tag of $4 million, representing the issuance of $2 million in stock and the assumption of approximately $2 million in debt.
For a smaller company like Cytori, a deal in this space hardly comes along every day—indeed, it’s the first acquisition ever for the 21-year-old company. But that’s also because the juiciest targets tend to go to the bigger players in this pricey space. Here are the top six corporate acquirers in the global pharma & biotech industry since the start of 2012:
Corporate M&A in pharma & biotech since 2012
Yarra Square Partners returned 19.5% net in 2020, outperforming its benchmark, the S&P 500, which returned 18.4% throughout the year. According to a copy of the firm's fourth-quarter and full-year letter to investors, which ValueWalk has been able to review, 2020 was a year of two halves for the investment manager. Q1 2021 hedge fund Read More
Since the start of 2012, corporate acquirers have completed 1,417 pharma & biotech transactions, according to the PitchBook Platform. Deal flow in the past five years peaked in 2015 at 388 transactions punctuated by AbbVie’s $21 billion hook up that May with Phamacyclics, a developer of treatments for cancer and immune-mediated inflammatory diseases. At 46% of all deals, the US represents the preponderance of activity in the industry, with the UK a distant second at 7%—Europe overall accounts for 32% of all deals.
PitchBook Platform users can access the full data on corporate investor activity in pharma & biotech.
Not a subscriber? Contact us today to set up a free demo.
Article by Adam Putz, PitchBook